Teva and prestige biopharma enter license agreement for tuznue® commercialization in europe

Teva and prestige announce a license and supply agreement for the commercialization of prestige's tuznue ® , a biosimilar to herceptin ® (trastuzumab) tuznue ® received european commission (ec) marketing authorization in september 2024 partnership brings together both companies' expertise in biosimilars tel aviv, israel, oct. 20, 2025 (globe newswire) -- teva pharmaceuticals international gmbh, a subsidiary of teva pharmaceutical industries ltd. (nyse: and tase: teva) entered into a license agreement with prestige biopharma, for the commercialization of tuznue® (trastuzumab), a biosimilar to herceptin®, across a majority of european markets.
TEVA Ratings Summary
TEVA Quant Ranking